Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | DRD3 | P35462 | 1/20 | 0.38 |
| ▸ | CYP11B1 | P15538 | 3/20 | 0.36 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.36 |
| ▸ | ACHE | P22303 | 2/20 | 0.35 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.35 |
| ▸ | IL1RN | P18510 | 1/20 | 0.31 |
| ▸ | ERAP2 | Q6P179 | 1/20 | 0.31 |
| ▸ | ERAP1 | Q9NZ08 | 1/20 | 0.31 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.31 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.31 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.31 |
| ▸ | HTR1A | P08908 | 1/20 | 0.30 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.30 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
| ▸ | KDM1A | O60341 | 2/20 | 0.30 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.30 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.30 |
| ▸ | KDM1B | Q8NB78 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1998740 | 0.79 | DRD2 (0.41) | DRD2DRD3CYP11B1CYP11B2ACHE | |
| SCHEMBL4666253 | 0.76 | DRD2 (0.53) | DRD2DRD3CYP11B1CYP11B2ACHE | |
| SCHEMBL30563612 | 0.76 | DRD2 (0.53) | DRD2DRD3CYP11B1CYP11B2ACHE | |
| SCHEMBL17702023 | 0.76 | DRD2 (0.53) | DRD2DRD3CYP11B1CYP11B2ACHE | |
| SCHEMBL1150855 | 0.76 | DRD2 (0.53) | DRD2DRD3CYP11B1CYP11B2ACHE | |
| SCHEMBL30327617 | 0.76 | DRD2 (0.53) | DRD2DRD3CYP11B1CYP11B2ACHE | |
| SCHEMBL193673 | 0.75 | DRD2 (0.43) | DRD2DRD3CYP11B1CYP11B2IL1RN | |
| SCHEMBL193672 | 0.75 | DRD2 (0.43) | DRD2DRD3CYP11B1CYP11B2IL1RN | |
| Hydrochloric Acid SCHEMBL17579984 | 0.74 | DRD2 (0.51) | DRD2DRD3CYP11B1CYP11B2ACHE | |
| Hydrochloric Acid SCHEMBL31186912 | 0.74 | DRD2 (0.51) | DRD2DRD3CYP11B1CYP11B2ACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120277190-A1 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR | ABBVIE INC. | 2012-11-01 | — | — | US | disclosed |
| US-8232309-B2 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBOTT LABORATORIES (US) | 2012-07-31 | — | — | US | disclosed |
| CN-102516176-A | Indazole derivatives that inhibit TRPVL receptor | ABBOTT LAB | 2012-06-27 | — | — | CN | disclosed |
| CN-101365684-A | Indazole derivatives inhibiting TRPV1 receptor | ABBOTT LAB (US) | 2009-02-11 | — | — | CN | disclosed |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | ABBVIE INC. | 2007-05-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120277190-A1 | PRODRUGS OF COMPOUNDS THAT INHIBIT TRPV1 RECEPTOR | TRPV1, TRPV3, TRPA1 | DRD2 793/4885DRD3 1111/4885CYP11B1 1704/4885 |
| US-20070099954-A1 | Prodrugs of compounds that inhibit TRPV1 receptor | TRPV1, TRPV3, TRPA1 | DRD2 793/4885DRD3 1111/4885CYP11B1 1704/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.